BREAKING NEWS: Pfizer Announces Upcoming U.S. Launch of Biosimilar INFLECTRA® (infliximab-dyyb)

more+
less-

Pfizer announced today that it will begin shipping INFLECTRA® (infliximab-dyyb) for injection, a biosimilar of REMICADE® (infliximab), to wholesalers in the United States (U.S.) in late November 2016.  INFLECTRA® received FDA approval this past April for the treatment of inflammatory conditions including Crohn’s disease, ulcerative colitis, and rheumatoid arthritis.  According to the announcement, INFLECTRA® will be introduced at a 15% discount to the current wholesaler acquisition cost (WAC) of REMICADE®, not inclusive of discounts to payers, providers, distributors and other purchasing organizations.

Stay tuned to Big Molecule Watch for more breaking news.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

more+
less-

Goodwin on:

JD Supra Readers' Choice 2016 Awards
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×